Summary
"Trying to do a (privatization) takeover at this point would be very challenging," said [Duncan Stewart]. Biovail "does produce cash flow, but there are significant concerns about the quality of the cash flow going forward."
His letter said he has "serious concerns about the ineffective exploitation of the depth and value of the company's world-class drug delivery technology," but efforts to reach him for comment have drawn no response. Biovail has declined to comment beyond saying the board has received [Eugene Melnyk]'s letter.See the full content of this document
Extract
Privatizing Biovail a Dicey Prescription: Analysts
By Eric Shackleton
TORONTO -- Analysts say it could prove challenging for Eugene Melnyk to take Biovail Corp. private, one of the option...See the full content of this document
Sponsored links
